Small renal masses progressing to metastases under active surveillance: A systematic review and pooled analysis

Cancer

Volumn 118, Issue 4, 2012, Pages 997-1006

  Smaldone, Marc C ^a   Kutikov, Alexander ^a   Egleston, Brian L ^a   Canter, Daniel J ^a   Viterbo, Rosalia ^a   Chen, David Y T ^a   Jewett, Michael A ^b   Greenberg, Richard E ^a   Uzzo, Robert G ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

active surveillance; metastasis; natural history; neoplasms; observation; progression

Indexed keywords

AGE; AGED; ARTICLE; CANCER GROWTH; FEMALE; HUMAN; KIDNEY METASTASIS; KIDNEY TUMOR; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PATIENT IDENTIFICATION; PATIENT MONITORING; PRIORITY JOURNAL; RENOGRAPHY; SYSTEMATIC REVIEW; TUMOR LOCALIZATION; TUMOR VOLUME; ANGIOMYOLIPOMA; COHORT ANALYSIS; DISEASE COURSE; DISEASE SURVEILLANCE; HEALTH HAZARD; LYMPH NODE METASTASIS; ONCOCYTOMA; TUMOR CLASSIFICATION; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RADIOGRAPHY; TUMOR BURDEN;

EID: 84856769912     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26369     Document Type: Article

References (62)

1. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A,. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010; 28: 126-131.
2. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG,. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006; 175: 425-431.
3. Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG,. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer. 2009; 115: 2844-2852.
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
5. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr,. Rising incidence of renal cell cancer in the United States. JAMA. 1999; 281: 1628-1631.
6. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK,. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006; 98: 1331-1334.
7. Jayson M, Sanders H,. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998; 51: 203-205.
8. Kutikov A, Fossett LK, Ramchandani P, et al. Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology. 2006; 68: 737-740.
9. Crispen PL, Boorjian SA, Lohse CM, et al. Outcomes following partial nephrectomy by tumor size. J Urol. 2008; 180: 1912-1917.
10. Remzi M, Ozsoy M, Klingler HC, et al. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol. 2006; 176: 896-899.
11. Hollenbeck BK, Taub DA, Miller DC, Dunn RL, Wei JT,. National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology. 2006; 67: 254-259.
12. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006; 7: 735-740.
13. McKiernan J, Simmons R, Katz J, Russo P,. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002; 59: 816-820.
14. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY,. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-1305.
15. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P,. Partial nephrectomy versus radical nephrectomy in patients with small renal tumorsâis there a difference in mortality and cardiovascular outcomes? J Urol. 2009; 181: 55-61; discussion 61-62.
16. Thompson RH, Boorjian SA, Lohse CM, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J. 2008; 179: 468-471; discussion 472-473.
17. Gill IS, Kavoussi LR, Lane BR, et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol. 2007; 178: 41-46.
18. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009; 182: 1271-1279.
19. Kunkle DA, Egleston BL, Uzzo RG,. Excise, ablate or observe: the small renal mass dilemmaâa meta-analysis and review. J Urol. 2008; 179: 1227-1233; discussion 1233-1234.
20. Kutikov A, Egleston BL, Wong YN, Uzzo RG,. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol. 2010; 28: 311-317.
21. Heuer R, Gill IS, Guazzoni G, et al. A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol. 2010; 57: 223-232.
22. Crispen PL, Viterbo R, Fox EB, Greenberg RE, Chen DY, Uzzo RG,. Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer. 2008; 112: 1051-1057.
23. Crispen PL, Wong YN, Greenberg RE, Chen DY, Uzzo RG,. Predicting growth of solid renal masses under active surveillance. Urol Oncol. 2008; 26: 555-559.
24. Kunkle DA, Crispen PL, Chen DY, Greenberg RE, Uzzo RG,. Enhancing renal masses with zero net growth during active surveillance. J Urol. 2007; 177: 849-853; discussion 853-854.
25. Rendon RA, Stanietzky N, Panzarella T, et al. The natural history of small renal masses. J Urol. 2000; 164: 1143-1147.
26. Mues AC, Haramis G, Badani K, et al. Active surveillance for larger (cT1bN0M0 and cT2N0M0) renal cortical neoplasms. Urology. 2010; 76: 620-623.
27. Abou Youssif T, Kassouf W, Steinberg J, Aprikian AG, Laplante MP, Tanguay S,. Active surveillance for selected patients with renal masses: updated results with long-term follow-up. Cancer. 2007; 110: 1010-1014.
28. Abouassaly R, Lane BR, Novick AC,. Active surveillance of renal masses in elderly patients. J Urol. 2008; 180: 505-508; discussion 508-509.
29. Beisland C, Hjelle KM, Reisaeter LA, Bostad L,. Observation should be considered as an alternative in management of renal masses in older and comorbid patients. Eur Urol. 2009; 55: 1419-1427.
30. Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J,. Small renal parenchymal neoplasms: further observations on growth. Radiology. 1995; 197: 589-597.
31. Fernando HS, Duvuru S, Hawkyard SJ,. Conservative management of renal masses in the elderly: our experience. Int Urol Nephrol. 2007; 39: 203-207.
32. Fujimoto N, Sugita A, Terasawa Y, Kato M,. Observations on the growth rate of renal cell carcinoma. Int J Urol. 1995; 2: 71-76.
33. Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y,. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol. 2004; 172: 863-866.
34. Kouba E, Smith A, McRackan D, Wallen EM, Pruthi RS,. Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention. J Urol. 2007; 177: 466-470; discussion 470.
35. Lamb GW, Bromwich EJ, Vasey P, Aitchison M,. Management of renal masses in patients medically unsuitable for nephrectomyânatural history, complications, and outcome. Urology. 2004; 64: 909-913.
36. Matsuzaki M, Kawano Y, Morikawa H, Shiga Y, Murata H, Komatsu H,. Conservative management of small renal tumors. Hinyokika Kiyo. 2007; 53: 207-211.
37. Oda T, Miyao N, Takahashi A, et al. Growth rates of primary and metastatic lesions of renal cell carcinoma. Int J Urol. 2001; 8: 473-477.
38. Rosales JC, Haramis G, Moreno J, et al. Active surveillance for renal cortical neoplasms. J Urol. 2010; 183: 1698-1702.
39. Siu W, Hafez KS, Johnston WK, 3rd, Wolf JS Jr,. Growth rates of renal cell carcinoma and oncocytoma under surveillance are similar. Urol Oncol. 2007; 25: 115-119.
40. Sowery RD, Siemens DR,. Growth characteristics of renal cortical tumors in patients managed by watchful waiting. Can J Urol. 2004; 11: 2407-2410.
41. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA,. The natural history of incidentally detected small renal masses. Cancer. 2004; 100: 738-745.
42. Wehle MJ, Thiel DD, Petrou SP, Young PR, Frank I, Karsteadt N,. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology. 2004; 64: 49-52.
43. Wong JA, Rendon RA,. Progression to metastatic disease from a small renal cell carcinoma prospectively followed with an active surveillance protocol. Can Urol Assoc J. 2007; 1: 120-122.
44. Morgenstern H,. Uses of ecologic analysis in epidemiologic research. Am J Public Health. 1982; 72: 1336-1344.
45. Sterne JA, Egger M, Smith GD,. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001; 323: 101-105.
46. Thompson SG, Sharp SJ,. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999; 18: 2693-2708.
47. Jewett MA, Finelli A, Morash C, et al. Active surveillance of small renal masses: a prospective multi-center Canadian Uro-Oncology Group trial [abstract]. J Urol. 2009; 181 (4 suppl (): 320. Abstract 890.
48. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H,. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003; 170 (6 pt 1): 2217-2220.
49. Lane BR, Babineau D, Kattan MW, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol. 2007; 178: 429-434.
50. Rothman J, Egleston B, Wong YN, Iffrig K, Lebovitch S, Uzzo RG,. Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol. 2009; 181: 29-33; discussion 33-34.
51. Thompson RH, Kurta JM, Kaag M, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol. 2009; 181: 2033-2036.
52. Nguyen MM, Gill IS,. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol. 2009; 181: 1020-1027; discussion 1027.
53. Duffey BG, Choyke PL, Glenn G, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol. 2004; 172: 63-65.
54. Friberg S, Mattson S,. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol. 1997; 65: 284-297.
55. Mues AC, Landman J,. Small renal masses: current concepts regarding the natural history and reflections on the American Urological Association guidelines. Curr Opin Urol. 2010; 20: 105-110.
56. Thompson RH, Hill JR, Babayev Y, et al. Metastatic renal cell carcinoma risk according to tumor size. J Urol. 2009; 182: 41-45.
57. Kunkle DA, Crispen PL, Li T, Uzzo RG,. Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol. 2007; 177: 1692-1696; discussion 1697.
58. Neuzillet Y, Lechevallier E, Andre M, Daniel L, Nahon O, Coulange C,. Follow-up of renal oncocytoma diagnosed by percutaneous tumor biopsy. Urology. 2005; 66: 1181-1185.
59. Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC,. Renal mass biopsyâa renaissance? J Urol. 2008; 179: 20-27.
60. Dechet CB, Zincke H, Sebo TJ, et al. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol. 2003; 169: 71-74.
61. Crispen PL, Blute ML,. Do percutaneous renal tumor biopsies at initial presentation affect treatment strategies? Eur Urol. 2009; 55: 307-309.
62. Uzzo RG,. Renal massesâto treat or not to treat? If that is the question are contemporary biomarkers the answer? J Urol. 2008; 180: 433-434.